134 related articles for article (PubMed ID: 38453361)
21. Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC.
Deininger K; Raacke JN; Yousefzadeh-Nowshahr E; Kropf-Sanchen C; Muehling B; Beer M; Glatting G; Beer AJ; Thaiss W
Nuklearmedizin; 2023 Oct; 62(5):284-292. PubMed ID: 37696296
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and Predictive Values of Metabolic Parameters of
Li X; Wang D; Yu L
Mol Imaging; 2019; 18():1536012119846025. PubMed ID: 31144578
[TBL] [Abstract][Full Text] [Related]
23. [18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer.
Mattonen SA; Davidzon GA; Bakr S; Echegaray S; Leung ANC; Vasanawala M; Horng G; Napel S; Nair VS
Tomography; 2019 Mar; 5(1):145-153. PubMed ID: 30854452
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
25. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
Yıldırım F; Yurdakul AS; Özkaya S; Akdemir ÜÖ; Öztürk C
Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685
[TBL] [Abstract][Full Text] [Related]
26. Metabolic tumor volume derived from
Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J
Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557
[TBL] [Abstract][Full Text] [Related]
27. Discovery of pre-therapy 2-deoxy-2-
Arshad MA; Thornton A; Lu H; Tam H; Wallitt K; Rodgers N; Scarsbrook A; McDermott G; Cook GJ; Landau D; Chua S; O'Connor R; Dickson J; Power DA; Barwick TD; Rockall A; Aboagye EO
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):455-466. PubMed ID: 30173391
[TBL] [Abstract][Full Text] [Related]
28. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
29. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
30. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R
Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201
[TBL] [Abstract][Full Text] [Related]
31. Multi-level multi-modality (PET and CT) fusion radiomics: prognostic modeling for non-small cell lung carcinoma.
Amini M; Nazari M; Shiri I; Hajianfar G; Deevband MR; Abdollahi H; Arabi H; Rahmim A; Zaidi H
Phys Med Biol; 2021 Oct; 66(20):. PubMed ID: 34544053
[TBL] [Abstract][Full Text] [Related]
32. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
33. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
34. The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.
Monaco L; De Bernardi E; Bono F; Cortinovis D; Crivellaro C; Elisei F; L'Imperio V; Landoni C; Mathoux G; Musarra M; Pagni F; Turolla EA; Messa C; Guerra L
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3401-3411. PubMed ID: 35403860
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
Seban RD; Assié JB; Giroux-Leprieur E; Massiani MA; Bonardel G; Chouaid C; Deleval N; Richard C; Mezquita L; Girard N; Champion L
Lung Cancer; 2021 Sep; 159():45-55. PubMed ID: 34311344
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive
Cui Y; Lin Y; Zhao Z; Long H; Zheng L; Lin X
Front Immunol; 2022; 13():994917. PubMed ID: 36466929
[TBL] [Abstract][Full Text] [Related]
37. Primary tumor standardized uptake value (SUVmax) measured on
Hui Z; Wei F; Ren H; Xu W; Ren X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
[TBL] [Abstract][Full Text] [Related]
38. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
Machtay M; Duan F; Siegel BA; Snyder BS; Gorelick JJ; Reddin JS; Munden R; Johnson DW; Wilf LH; DeNittis A; Sherwin N; Cho KH; Kim SK; Videtic G; Neumann DR; Komaki R; Macapinlac H; Bradley JD; Alavi A
J Clin Oncol; 2013 Oct; 31(30):3823-30. PubMed ID: 24043740
[TBL] [Abstract][Full Text] [Related]
39. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of
Ling T; Zhang L; Peng R; Yue C; Huang L
Front Immunol; 2022; 13():1014063. PubMed ID: 36466905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]